Overview

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

Status:
Completed

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

Summary

To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.

Phase:

Phase 1

Details

Lead Sponsor:

NuPathe Inc.

Treatments:

Sumatriptan